SEC Filings
Pictet Discloses 5.2% Elastic Stake, Says It Is Engaging The Board But Seeks No Control
A Schedule 13D covers 5,445,175 shares bought for clients, with talks on strategy, governance and valuation, and a right to change course.
SEC Filings
A Schedule 13D covers 5,445,175 shares bought for clients, with talks on strategy, governance and valuation, and a right to change course.
SEC Filings
The renamed company moved its Class B shares to the NYSE as SKYD and cut its $49.0 billion bridge loan to zero.
SEC Filings
BioLife has ceased to exist as a separate legal entity and asked Nasdaq to delist its stock, an 8-K shows.
SEC Filings
A proxy supplement adds cash, debt and discount-rate inputs behind Cantor's Supernus and Indivior valuations after two New York lawsuits.
SEC Filings
The Laredo bank holding company told Nasdaq it will withdraw its listing; no shareholder action is required.
SEC Filings
An 8-K says Hamill, who led about 2,500 Gilead staff, takes a Class I seat on December 1, 2026, replacing Yonatan Malca.
SEC Filings
Kevin Lobo becomes Executive Chair on January 1, 2027, keeping his pay terms but losing eligibility for new stock awards.
SEC Filings
An 8-K shows the partners settled Regeneron's Dupixent information lawsuit and will split global profits equally on four new antibodies.
SEC Filings
The final share count depends on trading prices through the repurchase period, with any remainder due by January 5, 2027.
SEC Filings
An 8-K says a finance subsidiary began the offering Tuesday, while CHF508.4 million of Swiss franc notes await issuance.
SEC Filings
The frozen-food maker also targets lower leverage on a path to 3.4X by 2029 and a long-term goal of becoming a €4 billion company.
SEC Filings
An 8-K says Holmes left the board and two committees to avoid conflicts, and that the exit was amicable.